Cencora, Inc the American drug wholesale company is grossly undervalued, according to Wolfteam Ltd.'s projections and estimates.
With 262.2 billion USD in revenue, growing at 9.89 %, net profit margin of 0.67 % for 2023, Cencora's net intrinsic value is 37 billion USD, compared with Cencora's current market capitalization of 9.88 billion USD.
Here is an excerpt from Cencora's second fiscal 2024 quarter earnings:
Cencora Reports Fiscal 2024 Second Quarter Results
5/1/2024
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year
Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80
Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 second quarter
ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted
accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in
the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,
increased 8.6 percent to $3.80 in the fiscal second quarter from $3.50 in the prior year second quarter
No comments:
Post a Comment